MBL International Corporation

MBL International Corporation (MBLI) is a leading player in the life science industry, focusing on providing high-quality products and solutions for researchers in various fields such as life sciences, drug discovery, development, and clinical diagnostics. As a JSR Life Sciences Company, MBLI is dedicated to improving the success rate, reducing timelines, and enhancing the efficacy of biologics-based therapies, especially in immunology, immuno-oncology, oncology, and autoimmune disease areas. The company's products widely cater to academic research and medical institutions, pharmaceutical and biotechnology companies, government agencies, as well as hospital and reference laboratories. Emphasizing stringent quality control, MBLI's diverse product line includes MHC monomers and multimers, antibodies, recombinant proteins, fluorescent proteins, and ELISA kits, offering extensive support for crucial research fields including oncology, allergy, apoptosis, autophagy, epigenetics, and neuroscience. Renowned for its immune monitoring reagents, such as MHC Tetramers and Monomers, and the QuickSwitch™ products, MBLI significantly contributes to acquiring reliable and reproducible immune monitoring results. This fosters advancements in immuno-oncology, autoimmune research, vaccine development, and beyond. Headquartered in Woburn, MA, with a manufacturing base in Des Plaines, IL, MBLI is committed to providing unwavering support to its customers through its scientific sales, customer service, and technical support teams, ensuring that they receive quality products and assistance promptly. With a founding year of 1993, MBL International operates primarily in the biotechnology and healthcare sectors. While there is no available information on the last investment or the last investors, the company's dedication to driving research and scientific advancements positions it as a compelling prospect for potential investors seeking to contribute to the advancement of life science research.